Last reviewed · How we verify
MRG006A
At a glance
| Generic name | MRG006A |
|---|---|
| Also known as | Pucotenlimab, Bevacizumab, PD1/VEGF antibody, TKI |
| Sponsor | Lepu Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) (PHASE1, PHASE2)
- A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRG006A CI brief — competitive landscape report
- MRG006A updates RSS · CI watch RSS
- Lepu Biopharma Co., Ltd. portfolio CI